|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A01N 55/02 | |
| A61K 31/555 | |||
| A61K 31/472 | |||
| A61K 31/4725 | |||
| A61K 38/13 | |||
| A61P 11/00 | |||
| A61P 17/00 | |||
| A61P 17/06 | |||
| A61P 17/14 | |||
| A61P 29/00 | |||
| A61P 19/02 | |||
| A61K 9/00 |
| (11) | Patento numeris | 2265125 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09733509.5 |
| Europos patento paraiškos padavimo data | 2009-04-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-12-29 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-08-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/002389 |
| Data | 2009-04-15 |
| (87) | Numeris | WO 2009/128934 |
| Data | 2009-10-22 |
| (30) | Numeris | Data | Šalis |
| 45240 | 2008-04-15 | US |
| (72) |
BURNIER, John, US
GADEK, Thomas, US
|
| (73) |
SARcode Bioscience Inc.,
1000 Marina Blvd., Suite 250, Brisbane, CA 94005,
US
|
| (54) | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS |
| TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS |